Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q3 FY2020 Earnings Presentation
15 slides from Morepen Laboratories's earnings presentation, Feb 17, 2020
Slide 1: Investors Presentation (Q3'FY20) cover letter to exchanges
.**.* ~ IAOREPEN Date: 17/02/2020 To, National Stock Exchange oflndia Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Tel No : (022) 26598100- 8114 Phones: 91-22-22721233 /4 Fax No: (022) 2659812
Slide 2: Investors Presentation (Q3'FY20) February 2020
“ I CHOOSE INVESTORS PRESENTATION (Q3’FY20) FEBRUARY 2020
Slide 3: Disclaimer
Disclaimer: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking
Slide 4: Highlights of Q3'FY20 Performance
Highlights of Q3’FY20 Performance ₹ crores • Net Sales Revenue in Q3’FY20 up by 9% at Rs. 226.91 crore as compared to Q3’FY19 . • Net Profit before tax up by 19.7% at Rs. 10.82 crore against Rs.9.04 crores in Q3’FY19 . • Cash Profits up by 2.8% at Rs. 19.36 crore against Rs.18.84 crores last year sa
Slide 5: Highlights of 9M'FY20 Performance
Highlights of 9M’FY20 Performance ₹ crores • Net Sales Revenue in 9M’FY20 up by 17.7% at Rs. 637.26 crore as compared to 9M’FY19 . • Net Profit before tax up by 50.2% at Rs. 27.74 crore against Rs.18.47 crores in 9M’FY19 . • Cash Profits up by 18.6% at Rs. 56.02 crore against Rs.47.23 crores in 9M’F
Slide 6: Segments wise growth
Segments wise growth: ₹ crores • Overall business for the Quarter (Q3’FY20) has grown at 9.4% as compared to Q3’FY19 235 9.4% • API Business has grown at 10% for the Q3’FY20 and still contributes 56% to the consolidated sales revenue and 62% to the standalone revenue including its exports. • Home Di
Slide 7: API: Domestic sale leads the way
API: Domestic sale leads the way API Revenues ₹ crores • API business retains its lion’s share of 57% and has grown at 10% on quarter on quarter basis. 131.96 10% • API Domestic business has got a jump of 76% with • Atorvastatin -146% • Montelukast - 70% • Loratadine - 39% • New Molecules - 334% gro
Slide 8: APAC Region outperforms in Exports
APAC Region outperforms in Exports ₹ crores API Export • Asia pacific Export business has got 54% share in the export business for the 9M’FY20 period and a jump of 21% as compared to 261.37 9M’FY19, with major growth registered from following markets: • Bangladesh 22% • Israel • China 213.97 • Sri L
Slide 9: Devices Business – Performance
Devices Business – Performance ₹ crores • Home Devices portfolio has maintained the same pace during the quarter compared 1% to same period last year . 42.87 • Nebuliser sales have marked a impressive growth of 89% in Q3’FY20 as against Q3’FY19. • Total Gluco monitors installed have crossed 3.30 mil
Slide 10: Prescription drugs sales up
Prescription drugs sales up Branded Formulations ₹ crores • Branded Prescription (Rx) products has grown by 35% during the Q3’FY’20 with major contribution coming from main brands like Salutm, Rhythmix, Klarim, Bacikid, 11.53 Metmore , Intebac and Cefopen. 35% • Overall Finished Dosages has grown by
Slide 11: OTC Business gains momentum
OTC Business gains momentum ₹ crores 17.65 • Total OTC category has registered a growth of 22% during the quarter . • Isabgol and Barnd Shaing have grown by 50% and 28% respectively . 22% • OTC Business has launched many new products to its Health Basket in the nutritional and preventive healthcare
Slide 12: Net Profit after tax rises
Net Profit after tax rises ₹ crores Net Consolidated Revenue • EBIDTA number has grown up by 18.5% during the 9M’FY20 as compared to corresponding 9M’FY19 . • Cash Profits during 9M’FY20 and Cash surplus has increased by 18.6% as 234.65 9.4% compared to 9M’FY19. • Net profit before tax has risen to
Slide 13: Q3'FY20 Performance - Standalone
Q3’FY20 Performance - Standalone ₹ crores Y-o-Y Y-o-Y Q3’FY20 Q3’FY19 Growth 9M’FY20 9M’FY19 Growth Net Revenue 218.09 200.76 8.6% 610.53 513.81 18.8% Expenditure 199.71 181.56 10% 554.72 466.21 18.9% EBIDTA 18.38 19.20 (4.2%) 55.81 47.60 17.2% Interest 0.54 0.42 29.7% 1.35 1.15 16.9% Cash Surplus 1
Slide 14: Q3'FY20 Performance - Consolidated
Q3’FY20 Performance - Consolidated ₹ crores Y-o-Y Y-o-Y Q3’FY20 Q3’FY19 Growth 9M’FY20 9M’FY19 Growth Net Revenue 234.65 214.59 9.4% 654.15 552.47 18.4% Expenditure 214.75 195.32 9.9% 596.77 504.05 18.4% EBIDTA 19.90 19.27 3.3% 57.38 48.41 18.5% Interest 0.54 0.43 27.7% 1.36 1.18 15.1% Cash Surplus
Slide 15: Thank You
Tran You Fat MOREDEN The Joy Of Growing Together
Morepen Laboratories — Q3 FY2020 Earnings Presentation on 6ix